Corrigendum to ‘First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis’
Title:
Corrigendum to ‘First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis’
Author:
Emens, L.A. Adams, S. Barrios, C.H. Diéras, V. Iwata, H. Loi, S. Rugo, H.S. Schneeweiss, A. Winer, E.P. Patel, S. Henschel, V. Swat, A. Kaul, M. Molinero, L. Patel, S. Chui, S.Y. Schmid, P.